Literature DB >> 31711239

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Michael R Drumm1, Karan S Dixit2, Sean Grimm2, Priya Kumthekar2, Rimas V Lukas2, Jeffrey J Raizer2, Roger Stupp2, Milan G Chheda3, Kwok-Ling Kam4, Matthew McCord4, Sean Sachdev5, Timothy Kruser5, Alicia Steffens1, Rodrigo Javier1, Kathleen McCortney1, Craig Horbinski1,4.   

Abstract

BACKGROUND: Progress in extending the survival of glioblastoma (GBM) patients has been slow. A better understanding of why patient survival remains poor is critical to developing new strategies. Postmortem studies on GBM can shed light on why patients are dying.
METHODS: The brains of 33 GBM patients were autopsied and examined for gross and microscopic abnormalities. Clinical-pathologic correlations were accomplished through detailed chart reviews. Data were compared with older published autopsy GBM studies that predated newer treatment strategies, such as more extensive surgical resection and adjuvant temozolomide.
RESULTS: In older GBM autopsy series, mass effect was observed in 72% of brains, with herniation in 50% of all cases. Infiltration of tumor into the brainstem was noted in only 21% of those older cases. In the current series, only 10 of 33 (30%) GBMs showed mass effect (P = 0.0003), and only 1 (3%) showed herniation (P < 0.0001). However, extensive GBM infiltration of the brainstem was present in 22 cases (67%, P < 0.0001), with accompanying destruction of the pons and white matter tracts. There was a direct correlation between longer median patient survival and the presence of brainstem infiltration (16.1 mo in brainstem-invaded cases vs 9.0 mo in cases lacking extensive brainstem involvement; P = 0.0003).
CONCLUSIONS: With improving care, severe mass effect appears to be less common in GBM patients today, whereas dissemination, including life-threatening brainstem invasion, is now more pronounced. This has major implications regarding preclinical GBM models, as well as the design of clinical trials aimed at further improving patient survival.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  autopsy; brainstem; glioblastoma; medulla; midbrain; pons; postmortem

Mesh:

Substances:

Year:  2020        PMID: 31711239      PMCID: PMC7158646          DOI: 10.1093/neuonc/noz216

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  30 in total

1.  Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma.

Authors:  Eric L Chang; Serap Akyurek; Tedde Avalos; Neal Rebueno; Chris Spicer; John Garcia; Robin Famiglietti; Pamela K Allen; K S Clifford Chao; Anita Mahajan; Shiao Y Woo; Moshe H Maor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-15       Impact factor: 7.038

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

Authors:  Kan V Lu; Jeffrey P Chang; Christine A Parachoniak; Melissa M Pandika; Manish K Aghi; David Meyronet; Nadezda Isachenko; Shaun D Fouse; Joanna J Phillips; David A Cheresh; Morag Park; Gabriele Bergers
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

4.  Symptoms and problems in the end-of-life phase of high-grade glioma patients.

Authors:  Eefje M Sizoo; Lies Braam; Tjeerd J Postma; H Roeline W Pasman; Jan J Heimans; Martin Klein; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2010-01-27       Impact factor: 12.300

5.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

6.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 7.  The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults.

Authors:  D L Silbergeld; R C Rostomily; E C Alvord
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

Review 8.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

9.  Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.

Authors:  Jacob J Mandel; Shlomit Yust-Katz; David Cachia; Jimin Wu; Diane Liu; John F de Groot; Alfred W K Yung; Mark R Gilbert
Journal:  J Neurooncol       Date:  2014-08-29       Impact factor: 4.130

10.  Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.

Authors:  Kengo Ogura; Takashi Mizowaki; Yoshiki Arakawa; Masakazu Ogura; Katsuyuki Sakanaka; Susumu Miyamoto; Masahiro Hiraoka
Journal:  Radiat Oncol       Date:  2013-04-23       Impact factor: 3.481

View more
  13 in total

1.  Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas".

Authors:  Jubayer A Hossain; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.

Authors:  Nikhil Rammohan; Alexander Ho; Mohit Saxena; Amishi Bajaj; Tim J Kruser; Craig Horbinski; Alexander Korutz; Matthew Tate; Sean Sachdev
Journal:  J Neurooncol       Date:  2022-05-07       Impact factor: 4.130

Review 3.  Disconnecting multicellular networks in brain tumours.

Authors:  Varun Venkataramani; Matthias Schneider; Ulrich Herrlinger; Frank Winkler; Frank Anton Giordano; Thomas Kuner; Wolfgang Wick
Journal:  Nat Rev Cancer       Date:  2022-04-29       Impact factor: 69.800

Review 4.  The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.

Authors:  Takahide Nejo; Abigail Mende; Hideho Okada
Journal:  Jpn J Clin Oncol       Date:  2020-10-22       Impact factor: 3.019

5.  Go, cancer stem cell, go! CSCs overcome myelin inhibition to move within white matter pathways.

Authors:  Daniel J Silver; Justin D Lathia
Journal:  Brain       Date:  2021-03-03       Impact factor: 15.255

Review 6.  Engineering Three-Dimensional Tumor Models to Study Glioma Cancer Stem Cells and Tumor Microenvironment.

Authors:  Henry Ruiz-Garcia; Keila Alvarado-Estrada; Paula Schiapparelli; Alfredo Quinones-Hinojosa; Daniel M Trifiletti
Journal:  Front Cell Neurosci       Date:  2020-10-16       Impact factor: 5.505

Review 7.  Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.

Authors:  Henry Ruiz-Garcia; Keila Alvarado-Estrada; Sunil Krishnan; Alfredo Quinones-Hinojosa; Daniel M Trifiletti
Journal:  Front Bioeng Biotechnol       Date:  2020-12-07

8.  GammaTile® brachytherapy in the treatment of recurrent glioblastomas.

Authors:  Dominic J Gessler; Elizabeth C Neil; Rena Shah; Joseph Levine; James Shanks; Christopher Wilke; Margaret Reynolds; Shunqing Zhang; Can Özütemiz; Mehmet Gencturk; Mark Folkertsma; W Robert Bell; Liam Chen; Clara Ferreira; Kathryn Dusenbery; Clark C Chen
Journal:  Neurooncol Adv       Date:  2021-12-27

9.  Quantification of Tissue Compression Identifies High-Grade Glioma Patients with Reduced Survival.

Authors:  Elies Fuster-Garcia; Ivar Thokle Hovden; Siri Fløgstad Svensson; Christopher Larsson; Jonas Vardal; Atle Bjørnerud; Kyrre E Emblem
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

10.  Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient.

Authors:  Matthew McCord; Rimas V Lukas; Christina Amidei; Nathan Demars; Arnold Gelb; Jill Buck; Sean Sachdev; Alexander Feldman; Matthew Tate; Karan Dixit; Daniel J Brat; Lawrence Jennings; Craig Horbinski
Journal:  Neurooncol Adv       Date:  2021-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.